F&O: Nifty forms higher highs, lows for 4th session, poised to gain more
Momentum oscillator RSI is moving northward and, thus, showing strength in the index.
Top intraday trading ideas for afternoon trade on Tuesday, December 17, 2019
Vedanta is a 'Buy' call with a target price of Rs 160 and a stop loss of Rs 145.
Cipla shares rise after Vysov anti-diabetic drug acquisition
Cipla has been co-marketing Vildagliptin in agreement with Novartis under brand names Vysov and Vysov M (Vildagliptin plus Metformin), the company said in a regulatory filing.
Stocks in the news: SBI, BPCL, RIL, Adani Green and IFB Industries
Morgan Stanley has an overweight rating on Reliance Industries with a target price of Rs 1,753.
Cipla gains as arm to buy 40% stake in Cipla Pharma Lanka
The stock moved 1.81 per cent higher to trade at Rs 476.50 on the NSE.
Share market update: Nifty Pharma index up; Biocon gains 2%
The Nifty Pharma index was trading 0.09 per cent up at 8253.90.
Aurobindo Pharma under USFDA scrutiny
Aurobindo has seen intense scrutiny on the manufacturer process of valsartan, an anti-hypertension drug, that was found to contain carcinogenic impurities. Apart from Aurobindo, those impurities were detected in several other batches manufactured by drug makers.
Buy Glenmark Pharma, price target Rs 375: Kunal Bothra
The analyst suggested a stoploss at Rs 340.
Share market update: Nifty Pharma index up; Biocon jumps 5%
The Nifty Pharma index was trading 0.63 per cent up at 8229.40.
With valuations rich elsewhere, is it time to swallow the bitter pill?
For investors seeking to nibble into pharma names, stock selection is going to be key.
USV in talks with Novartis to buy Jalra Trademark for Rs. 200 Crore
Mumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal valued at more than Rs. 200 crore.
Sensex rises 70 points, Nifty tops 12,100; IT stocks gain
Most sectoral indices were also up with Nifty IT being the biggest gainer.
Glenmark Pharma jumps 21% on CLSA upgrade
YES Securities is also positive on Glenmark Pharma with a 12-month target price of Rs 340.
Share market update: Nifty Pharma index dips; Piramal Enterprises down 2%
The Nifty Pharma index was trading 0.07 per cent down at 8123.
Share market update: Nifty Pharma index up; Lupin gains 3%
The Nifty Pharma index was trading 0.66 per cent up at 8265.65 .
Copyright © 2020 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service